NASDAQ:CING Cingulate Q3 2026 Earnings Results & Report $3.81 -0.49 (-11.40%) As of 12:17 PM Eastern This is a fair market value price provided by Massive. Learn more. Cingulate missed analyst earnings expectations in its Q3 2026 results, released November 13, 2026. The company reported EPS of -$0.53 versus the -$0.4325 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2026Report DateNovember 13, 2026TimeAfter Market ClosesConference Call7:00 AM ET Cingulate EPS ResultsActual EPS-$0.53Consensus EPS -$0.4325Beat/MissMissed by -$0.0975One Year Ago EPSN/AEPS Beat Rate2 of last 8 quartersCingulate Revenue ResultsActual RevenueN/AExpected Revenue$540 thousandBeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Cingulate Q3 2026 Earnings FAQ Did Cingulate beat earnings estimates for Q3 2026? Cingulate (NASDAQ:CING) reported earnings of -$0.53 per share for Q3 2026, missing the consensus estimate of -$0.4325. The report was announced on Friday, November 13, 2026. Cingulate Earnings HeadlinesCingulate Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026November 15 at 9:42 AM | marketscreener.comMCingulate Inc. Reports Q3 2026 Results, Says CTx-1301 NDA Resubmission Expected Between December 2026 and January 2027November 13 at 4:51 PM | quiverquant.comQWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and the shift is already underway. The dollar has lost 88% of its purchasing power since it was untethered from gold, and Fortune calls the current change the biggest shift in the world's relationship with the dollar in a generation. Stansberry says a similar reset is planned to be unveiled in Miami as soon as this December. Watch Porter Stansberry's full broadcast to see which companies could be affected.November 16 at 1:00 AM | Porter & Company (Ad)Cingulate Inc. Reports Third Quarter 2026 Financial Results and Provides Regulatory Update on CTx-1301 NDA ResubmissionNovember 13 at 4:45 PM | globenewswire.comShane Schaffer, Cingulate Chairman and CEO, Provides Update on CTx-1301 in Interview with Innovators with Jane KingNovember 10, 2026 | finance.yahoo.comCingulate (NASDAQ:CING) Stock Gets Downgrade from Wall Street ZenNovember 7, 2026 | americanbankingnews.comSee More Cingulate Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Cingulate? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cingulate and other key companies, straight to your email. Email Address About CingulateCingulate (NASDAQ:CING) is a clinical-stage biopharmaceutical company developing prescription treatments for attention-deficit/hyperactivity disorder (ADHD). The company’s approach is to improve how existing medicines are delivered over the course of the day. Its lead candidate, CTx-1301, is an extended-release formulation of dexmethylphenidate designed to provide multiple timed releases of medication. Cingulate is also developing CTx-1302, another candidate for ADHD. The company uses its proprietary Precision Timed Release drug-delivery platform to develop these candidates. Cingulate is based in the United States and is focused on advancing its therapies through clinical development.View Cingulate ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles 3 Building-Materials Stocks Rallying While Homebuilders Struggle to Find BuyersMarketBeat Week in Review – 11/9 - 11/133 AI Hardware Leaders Are Raising Dividends, But Which Offers More Income?Nu Holdings Earnings Show a Compounder Priced Like a Brazil BetCould Big Buybacks Be the Next Catalyst for These 3 AI Stocks?Cerebras Q3 Results: How Much More Proof Does Wall Street Need?Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions Upcoming Earnings Walt Disney (11/17/2026)Home Depot (11/17/2026)NVIDIA (11/17/2026)Lowe's Companies (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026)Palo Alto Networks (11/18/2026)NetEase (11/19/2026)Alibaba Group (11/19/2026)PDD (11/19/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.